DelMar reports Phase II data for VAL-083 in recurrent GBM

DelMar Pharmaceuticals Inc. (NASDAQ:DMPI) reported data from 22 evaluable patients with recurrent glioblastoma multiforme (GBM) in a Phase II trial showing that VAL-083 (dianhydrogalactitol) led to stable disease as a best response in seven patients. Data were presented at the American Association for Cancer Research meeting in Chicago.

The open-label, U.S. trial is enrolling about 48 patients with O6-alkylguanine alkyltransferase (MGMT)-unmethylated, Avastin bevacizumab-naïve, recurrent GBM to receive 40 mg/m² IV VAL-083 on days 1-3 of each 21-day cycle for up to 12 cycles...